Programa de asistencia para pacientes de Novo Nordisk PO Box 181640 Louisville, KY 40261 Teléfono: 866-310-7549 Fax: 866-441-4190 Instrucciones: Por favor, asegúrese de completar las dos paginas de esta solicitud. Las solicitudes incompletas serán devueltas. · Por favor, calcule hasta 10 días laborables para procesamiento y envío del medicamento a la oficina del pr
Doi:10.1016/j.transproceed.2004.06.039Primary Immunosuppression Regimen of Rapid Steroid Withdrawal
After Living Related Liver Transplantation: A Single-Center Experience
Y. Toyoki, K. Hakamada, S. Narumi, E. Totsuka, M. Nara, H. Ono, Y. Ishizawa, M. Sasaki Corticosteroids have been considered the mainstay of immunosuppressive therapy after liver transplantation. However, the side effects of long-term steroid use such asdiabetes, infections, and bone disease, including growth retardation in children, are seriousproblems. Our immunosuppression regimen includes FK506 and steroid withdrawal by 30days after transplantation. The aim of this study was to determine the outcomes of livertransplant, using this immunosuppressive regimen.
Fifteen primary liver transplant recipients were performed between January 1994 and May 2003 and data were reviewed retrospectively. Eight pediatric and four adultrecipients, who had survived more than 3 months after transplantation, were included inthis sample. The immunosuppressive regimen consisted of FK 506 (Prograf), initially atdoses of 0.03 mg/kg, with dose adjustments to achieve daily trough levels of approximately10 to 12 ng/mL, and predonisone, initially at 4 mg/kg/d, with a taper and cessation by 30days when the graft was stable.
All recipients were successfully withdrawn by 30 days. Acute rejection episodes occurred in three patients, no patient was diagnosed with chronic rejection. The acuterejection-free rate at 5 year was 74.1%. No recipient had diabetes, serious infections orbone disease.
Our primary immunosuppressive regimen of rapid steroid withdrawal is safe with regard to acute and chronic rejection with benefits upon steroid-related sideeffects.
ORTHOTOPIC LIVER TRANSPLANTATION is a nosuppression regimen is initiated with FK506 with steroid commonly accepted therapy for patients with end- withdrawal by 30 days after transplantation.
stage liver disease. Immunosuppressive drugs, includingcorticosteroids, have contributed to the success of liver transplantation. Corticosteroids are still considered a main- The records of eight pediatric and seven adult primary liver stay of immunosuppressive therapy after liver transplanta- recipients who received transplants between January 1, tion. However, their side effects such as diabetes, suscepti- 1994, and August 31, 2003, were reviewed retrospectively.
bility to infections, hypercholesterolemia, and bone disease, Three adult liver transplant recipients died within 3 months including growth retardation in children, are serious prob- after living related liver transplantation: two cases due to lems. Therefore, adequate immunosuppressive therapy, in- portal vein thrombosis, and one case due to infectious cluding avoidance of these steroid-related side effects, is a myocarditis. Finally, eight pediatric and four adult recipi- goal in long-term management of organ transplant recipi-ents. Some reports indicate that maintenance immunosup- From the Department of Surgery, Hirosaki University School of pression without steroids has the advantage of no steroid- related side effects without an increased incidence of Address reprint requests to Yoshikazu Toyoki, Department of rejection and graft The timing of steroid withdrawal Surgery, Hirosaki University School of Medicine, 5 Zaifu-cho, varies between liver transplant centers, but is generally Hirosaki, Aomori 036-8216, Japan. E-mail: email@example.com- performed after 3 months post transplantation. Our immu- 2004 by Elsevier Inc. All rights reserved.
360 Park Avenue South, New York, NY 10010-1710 Transplantation Proceedings, 36, 2279 –2281 (2004) Table 1. Demographic Characterization of Our Recipients
PSC, primary sclerosing cirrhosis; LC, liver cirrhosis; SAFHF, subacute fulminant hepatic failure; NNH, neonatal hepatitis; LOHF, late-onset hepatic failure.
ents who had survived and were followed more than 3 Renal Function and Immunosuppression-Related months after living related liver transplantation were in- cluded in this study. Patient age, gender, and the primary Fasting serum creatinine levels as well as renal function diagnosis for liver transplantation are shown in have remained within the normal range though the post- Median follow-up is 52.652 months (6.441 to 114.477 transplantation periods. Nine liver transplant recipients had months). Our immunosuppression regimen consisted of FK no immunosuppression related complications; however, 506 (Prograf), initially at doses of 0.03 mg/kg with dose one adolescent recipient experienced a CMV infection; one adjustments to achieve daily trough levels of approximately pediatric recipient a candida infection; and one other 10 to 12 ng/mL, and predonisone, initially at 4 mg/kg/d, with patient, an episode of convulsions. All three patients recov- a taper and cessation of steroid therapy by 30 days post- transplantation if the graft was stable. We conducted thisretrospective review to determine whether our immunosup-pressive regimen with rapid steroid withdrawal was safe to suppress acute and chronic rejection among both adult andchild recipients of living related liver transplantation and to The acute rejection free rate at 5 years was 74.1% Two recipients were diagnosed with acute rejection patientswithin the first month after liver transplantation, and one at 6 months after steroid withdrawal. All three recipientsexperienced only one acute rejection that reversed with a All recipients underwent steroid withdrawal by 30 to 70 steroid pulse alone. No patients were diagnosed with days after liver transplantation. Currently 10 recipients are maintained on FK506 alone and one recipient on pre-donisolone alone. One recipient was completely withdrawnfrom immunosuppressive therapy and his graft function isstable. Three recipients were diagnosed with acute rejectionepisodes and no patients with chronic rejection. None of therecipients showed diabetes, serious infections, or bonedisease.
Serum alanine aminotransferase and total bilirubin of allrecipients remained within the normal range from 3 monthsoccurred after transplantation. During the first 6 monthsafter transplantation, FK506 trough levels were 10 to 12ng/mL and at 24 months after transplantation they rangefrom 4 to 6 ng/mL.
Fasting Serum Cholesterol and Blood Glucose Fasting serum cholesterol and blood glucose levels haveremained within the normal range though the posttrans-plant periods.
Acute rejection, free rate at 5 years was 74.1%.
glucose levels remained normal after steroid withdrawal.
FK506 trough levels ranged from 4 to 6 ng/mL since year 2 For more than 25 years, liver transplantation has been after liver transplantation. We have not seen serious ste- recognized as the accepted therapy for end-stage liver roid-related side effects, such as hyperglycemia or bone disease in both adults and children. With newer and more efficient immunosuppressive therapies, the optimal regi- The potential benefits of steroid withdrawal are directly mens should be reconsidered for long-term liver transplant related to their side effects, especially to produce growth recipients. Avoidance of steroid-related side effects is a goal retardation in pediatric recipients. Vo Thi Diem et al in the long-term management of organ transplant recipi- reported an improvement in growth after steroid withdraw- ents. Some reports indicate that maintenance immunosup- There was an improvement in height z-score among our pression without steroids has the advantage of no steroid- pediatric recipients, except one patient who has growth related side effects without an increased incidence of retardation due to nonalcoholic steatohepatitis after liver rejection and graft The timing of steroid withdrawal varies between liver transplant centers, but is generally In summary, our primary immunosuppressive regimen performed beyond 3 months after transplantation. Our with rapid steroid withdrawal for both adult and child immunosuppression regimen is initiated with FK506 and recipients of living related liver transplantation suppresses steroid withdrawal occurs about 30 days after transplanta- acute and chronic rejection and avoids steroid-related side tion. The purpose of this study was to review our experience to determine the characteristics of these patients.
In this study, all liver transplant recipients had an attempt at steroid withdrawal by 30 days. Two recipients experi-enced acute rejection within 30 days after liver transplan- 1. Fraser GM, Grammonstianos K, Reddy J, et al: Liver Transpl tation and were weaned from steroids at 60 and 68 days 2. Stegall MD, Everson GT, Schorter G, et al: Hepatology after transplantation. Only one patient experienced acute rejection at 6 months after steroid withdrawal. The acute 3. Gomez R, Moreno E, Colina F, et al: J Hepatol 28:150, 1998 rejection free rate at 5 years was 74.1%. No recipients had 4. Tisone G, Angelico M, Palmieri G, et al: Transplantation been diagnosed with chronic rejection. In our data, liver 5. Vo Thi Diem H, Sokal EM, Janssen M, et al: Transplantation and renal function, fasting serum cholesterol, and blood
T I P S H E E T www.healthinaging.org Expert information from Healthcare Professionals Who Specialize in the Care of Older Adults Ten Medications Older Adults Should Avoid or Use with Caution Because older adults often experience chronic health conditions that require treatment with multiple medications, there is a greater likelihood of experiencing unwanted drug side effects. Ol